Salvage radical prostatectomy for radiation-recurrent prostate cancer: A multi-institutional collaboration

Daher C. Chade, Shahrokh F. Shariat, Angel M. Cronin, Caroline J. Savage, R. Jeffrey Karnes, Michael L. Blute, Alberto Briganti, Francesco Montorsi, Henk G. Van Der Poel, Hendrik Van Poppel, Steven Joniau, Guilherme Godoy, Antonio Hurtado-Coll, Martin E. Gleave, Marcos Dall'Oglio, Miguel Srougi, Peter T. Scardino, James A. Eastham

Research output: Contribution to journalArticle

122 Scopus citations

Abstract

Background: Oncologic outcomes in men with radiation-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP) are poorly defined. Objective: To identify predictors of biochemical recurrence (BCR), metastasis, and death following SRP to help select patients who may benefit from SRP. Design, setting, and participants: This is a retrospective, international, multi-institutional cohort analysis. There was a median follow-up of 4.4 yr following SRP performed on 404 men with radiation-recurrent PCa from 1985 to 2009 in tertiary centers. Intervention: Open SRP. Measurements: BCR after SRP was defined as a serum prostate-specific antigen (PSA) ≥0.1 or ≥0.2 ng/ml (depending on the institution). Secondary end points included progression to metastasis and cancer-specific death. Results and limitations: Median age at SRP was 65 yr of age, and median pre-SRP PSA was 4.5 ng/ml. Following SRP, 195 patients experienced BCR, 64 developed metastases, and 40 died from PCa. At 10 yr after SRP, BCR-free survival, metastasis-free survival, and cancer-specific survival (CSS) probabilities were 37% (95% confidence interval [CI], 31-43), 77% (95% CI, 71-82), and 83% (95% CI, 76-88), respectively. On preoperative multivariable analysis, pre-SRP PSA and Gleason score at postradiation prostate biopsy predicted BCR (p = 0.022; global p < 0.001) and metastasis (p = 0.022; global p < 0.001). On postoperative multivariable analysis, pre-SRP PSA and pathologic Gleason score at SRP predicted BCR (p = 0.014; global p < 0.001) and metastasis (p < 0.001; global p < 0.001). Lymph node involvement (LNI) also predicted metastasis (p = 0.017). The main limitations of this study are its retrospective design and the follow-up period. Conclusions: In a select group of patients who underwent SRP for radiation-recurrent PCa, freedom from clinical metastasis was observed in >75% of patients 10 yr after surgery. Patients with lower pre-SRP PSA levels and lower postradiation prostate biopsy Gleason score have the highest probability of cure from SRP.

Original languageEnglish (US)
Pages (from-to)205-210
Number of pages6
JournalEuropean urology
Volume60
Issue number2
DOIs
StatePublished - Aug 1 2011

    Fingerprint

Keywords

  • Prostate cancer
  • Radiation therapy
  • Salvage therapy

ASJC Scopus subject areas

  • Urology

Cite this

Chade, D. C., Shariat, S. F., Cronin, A. M., Savage, C. J., Karnes, R. J., Blute, M. L., Briganti, A., Montorsi, F., Van Der Poel, H. G., Van Poppel, H., Joniau, S., Godoy, G., Hurtado-Coll, A., Gleave, M. E., Dall'Oglio, M., Srougi, M., Scardino, P. T., & Eastham, J. A. (2011). Salvage radical prostatectomy for radiation-recurrent prostate cancer: A multi-institutional collaboration. European urology, 60(2), 205-210. https://doi.org/10.1016/j.eururo.2011.03.011